Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease



Status:Recruiting
Conditions:Parkinsons Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:55 - 85
Updated:4/17/2018
Start Date:June 2012
End Date:December 2018
Contact:Laura Wulf, MA
Email:l-wulf@northwestern.edu
Phone:312-503-1999

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
Disruption of sleep and alertness is one of the most disabling non-motor symptoms of
Parkinson's disease (PD). Mechanisms leading to impaired sleep and alertness in PD are not
well understood, and treatment options remain limited. The proposed research will examine
markers of the circadian system, sleepiness and sleep quality in PD patients and healthy
controls. Further, the project will examine effects of bright light exposure on circadin
function, sleep and alertness in PD.


Inclusion Criteria:

1. Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank
Criteria;

2. PD Hoehn and Yahr stage 2-4;

3. Pittsburgh Sleep Quality Index (PSQI) score >5 in group 1, and ≤5 in group 2;

4. Epworth Sleepiness Scale (ESS) score ≥10 in group 1, and <10 in group 2;

Control participants will be matched for gender and age with PD participants.

Exclusion Criteria:

1. Atypical or secondary forms of Parkinsonism;

2. Cognitive impairment as determined by the Mini-Mental State Examination (MMSE) score
of ≤ 26;

3. Presence of depression defined as the Beck Depression Inventory (BDI) score >14;

4. Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to
taper these drugs and will become eligible at least 4 weeks after the taper is
completed;

5. Use of SSRIs / SNRIs antidepressants, unless the participant has been on a stable dose
for at least 3 months prior to the screening;

6. Use of medications known to affect melatonin secretion;

7. Unstable/serious medical illness.
We found this trial at
1
site
Northwestern University
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Aleksandar Videnovic, MD
?
mi
from
Chicago, IL
Click here to add this to my saved trials